88 FR 112 pgs. 38096-38097 - Notice Pursuant to the National Cooperative Research and Production Act of 1993

Next Article Next

88 FR 112 pgs. 38096-38097 - Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium

Type: NOTICEVolume: 88Number: 112Pages: 38096 - 38097

FR document: [FR Doc. 2023-12504 Filed 6-9-23; 8:45 am]

Agency: Justice Department

Sub Agency: Antitrust Division

Official PDF Version: PDF Version

Pages: 38096, 38097

[top]

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium

[top] Notice is hereby given that, on April 6, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), Medical CBRN Defense Consortium ("MCDC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under

specified circumstances. Specifically, Decryptor, Inc., Richardson, TX; Joint Research & Development, Inc., Stafford, VA; Northstar Emergency Management LLC, Pittsburgh, PA; Redwire Space Components LLC, Marlborough, MA; SaponiQx, Inc., Lexington, MA; UniVox Technical Solutions LLC dba UniVox LLC, Tijeras, NM; Vega Technology Group LLC, North Canton, OH; and Zalgen Labs LLC, Frederick, MD have been added as parties to this venture.

Also, Allegheny-Singer Research Institute dba AHN Institute, Pittsburgh, PA; BioCryst Phamaceuticals, Inc., Durham, NC; Encryptor, Inc., Richardson, TX; Healion Bio, Inc., Ijamsville, MD; ImmPORT Therapeutics, Inc. dba Antigen Discovery, Inc., Irvine, CA; Kuprion, Inc., San Jose, CA; MBio Diagnostics, Inc. dba LightDeck Diagnostics, Boulder, CO; Medicago USA, Inc., Durham, NC; Merck, Sharpe and Dohme Corp., Whitehouse Stations, NJ; and Tutela Pharmaceuticals, Inc., Vernon Hills, IL have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership.

On November 13, 2015, MCDC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on January 6, 2016 (81 FR 513).

The last notification was filed with the Department on January 4, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on January 25, 2023 (88 FR 4850).

Suzanne Morris,

Deputy Director, Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023-12504 Filed 6-9-23; 8:45 am]

BILLING CODE P